MET as an Oncogenic Driver The MET gene, encoding a receptor tyrosine kinase, can drive non-small cell lung cancer (NSCLC) through two distinct mechanisms: exon 14 skipping mutations (METex14) that impair receptor degradation, and MET gene amplification (METamp) that increases receptor copy number. Both lead to constitutive MET signaling but through different molecular mechanisms.
Clinical Relevance METex14 alterations are actionable therapeutic targets, with MET inhibitors such as capmatinib and tepotinib now approved for METex14-positive NSCLC. METamp is associated with resistance to EGFR-targeted therapies and may also respond to MET inhibition, but the clinical behavior of the two subtypes differs markedly.
Study Scale This large-scale analysis examined 18,047 NSCLC tumor samples with comprehensive molecular profiling. METex14 was identified in 276 tumors (1.53%), high-level METamp in 138 tumors (0.76%), and low-level METamp in 63 tumors (0.35%), providing sufficient cohort sizes for meaningful comparative analysis.
Multi-Omic Approach The genomic landscape (mutations, copy number, structural variants), immune microenvironment characteristics (tumor mutational burden, immune cell infiltration, neoantigen burden, PD-L1 expression), and co-occurring genomic alterations were all systematically compared between METex14 and METamp subtypes.
METex14 Demographics METex14-positive patients were significantly older and included higher proportions of female patients and non-smokers compared to other NSCLC subtypes. This demographic profile is consistent with the established clinical phenotype of METex14 NSCLC, which resembles EGFR-mutant lung cancer in its enrichment among never-smokers.
Lowest Tumor Mutational Burden METex14 tumors had the lowest tumor mutational burden (TMB) among all NSCLC subtypes analyzed, with a median TMB of 2.6 mutations per megabase. Low TMB is associated with fewer neoantigens and reduced immunogenicity, which may limit the effectiveness of immune checkpoint inhibitors.
Minimal Neoantigen Burden Consistent with low TMB, METex14 tumors also had the lowest neoantigen burden. Neoantigens are tumor-specific peptides recognized by T cells as foreign - low neoantigen load means immune surveillance of these tumors is fundamentally limited.
Mutual Exclusivity with Other Drivers METex14 alterations were largely mutually exclusive with other common NSCLC driver mutations including EGFR, KRAS, and ALK. This confirms METex14 as a standalone driver rather than a co-driver, consistent with the single-oncogene dependency that makes it a predictive biomarker for MET inhibitor response.
High METamp Immune Features High-level METamp tumors showed the lowest CD4+ T cell infiltration among all groups, suggesting an immune-excluded microenvironment. CD4+ helper T cells are critical for sustaining anti-tumor immune responses, and their depletion may explain the poor response of METamp tumors to immunotherapy.
Elevated NK Cell Infiltration Despite low CD4+ T cells, METamp tumors had higher NK cell infiltration. NK cells provide innate anti-tumor immunity and can kill tumor cells without prior sensitization. Whether this NK cell enrichment translates to clinical benefit in METamp NSCLC requires further investigation.
Higher PD-L1 Positivity METamp tumors showed higher PD-L1 expression positivity rates compared to METex14 tumors. While PD-L1 positivity is conventionally used to select patients for checkpoint inhibitors, the co-occurring low CD4+ T cell infiltration in METamp may limit the functional immune response even when PD-L1 is high.
EGFR Co-Alterations Approximately 28% of METamp tumors harbored co-occurring EGFR alterations. This is clinically important because METamp is a known mechanism of acquired resistance to EGFR TKIs, and the prevalence of EGFR co-alterations supports METamp's role as a resistance driver in the EGFR-mutant setting.
METex14 and Checkpoint Inhibitor Limitations The very low TMB and neoantigen burden in METex14 NSCLC provide a mechanistic explanation for the historically poor responses to PD-1/PD-L1 inhibitors observed clinically. With few neoantigens to trigger T cell responses, checkpoint blockade has little pre-existing immunity to amplify.
METamp Immunotherapy Paradox The combination of higher PD-L1 expression and low CD4+ T cell infiltration in METamp creates an immunological paradox. PD-L1 positivity would suggest checkpoint inhibitor benefit, but the absence of CD4+ T helper cells may mean that even if T cell suppression is relieved, the adaptive immune response cannot be effectively mounted.
Treatment Algorithm Implications These findings support prioritizing MET inhibitor monotherapy over immunotherapy for METex14 patients and suggest caution when using PD-L1 alone to select METamp patients for checkpoint inhibitors without considering the full immune cell landscape.
NK Cell Targeting Opportunity The elevated NK cell infiltration in METamp tumors raises the possibility of NK cell-activating therapies as a complementary approach. Bispecific antibodies or NK cell engagers could potentially exploit this pre-existing NK cell presence to drive innate immune tumor killing.
METamp as a Resistance Mechanism The 28% EGFR co-alteration rate in METamp confirms the established role of MET amplification as a bypass resistance mechanism in EGFR-mutant NSCLC. Patients whose EGFR-targeted therapy fails due to acquired METamp represent a defined clinical population that may benefit from MET plus EGFR dual inhibition.
Combinatorial Treatment Strategies For EGFR-mutant patients who develop METamp resistance, combining an EGFR inhibitor (such as osimertinib) with a MET inhibitor (such as savolitinib) has shown clinical activity. The genomic landscape data in this study supports biomarker-stratified enrollment into such combination trials.
METex14 as a Pure Driver The mutual exclusivity of METex14 with other drivers confirms it as the primary and often sole oncogenic driver in affected tumors. This supports aggressive MET inhibitor monotherapy as the standard approach, as there is no concurrent driver that might provide an alternative escape pathway.
Low-Level METamp Uncertainty The study's inclusion of low-level METamp as a separate group (n=63) highlights the biological ambiguity of this category - low copy gain may represent polysomy or focal amplification with varying functional significance, and its optimal management remains unclear.
Retrospective Nature As a large retrospective genomic database analysis, this study cannot establish causal relationships between molecular characteristics and clinical outcomes. Prospective cohorts with standardized treatment and outcome data are needed to validate the clinical implications of the observed genomic and immune differences.
Treatment Outcome Integration The study characterizes the molecular landscape but does not systematically report treatment responses or survival outcomes stratified by the identified features. Linking these molecular profiles to immunotherapy and MET inhibitor response data would directly test the clinical hypotheses generated.
Spatial Immune Analysis Bulk immune cell quantification does not capture spatial context - whether immune cells are present within the tumor (inflamed) or at the periphery (excluded) determines their functional impact. Spatial transcriptomics or multiplex imaging of MET-altered tumors would provide deeper mechanistic insights.
Emerging MET Inhibitors As more MET inhibitors enter clinical development and combination strategies are tested, the immune and genomic landscape data from this study could guide patient selection for clinical trials. Prospective biomarker studies in MET inhibitor trials are a natural application.